Goldman Sachs’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-402,581
| Closed | -$1.82M | – | 6416 |
|
|
2025
Q3 | $1.82M | Sell |
402,581
-94,706
| -19% | -$279K | ﹤0.01% | 4569 |
|
|
2025
Q2 | $1.07M | Buy |
497,287
+36,457
| +8% | +$102K | ﹤0.01% | 4647 |
|
|
2025
Q1 | $2.01M | Sell |
460,830
-39,880
| -8% | -$180K | ﹤0.01% | 4157 |
|
|
2024
Q4 | $2.34M | Buy |
500,710
+76,623
| +18% | +$516K | ﹤0.01% | 4151 |
|
|
2024
Q3 | $2.98M | Buy |
424,087
+27,156
| +7% | +$197K | ﹤0.01% | 3796 |
|
|
2024
Q2 | $2.72M | Buy |
+396,931
| New | +$3.69M | ﹤0.01% | 3692 |
|
|
2024
Q1 | – | Sell |
-455,279
| Closed | -$3.43M | – | 5531 |
|
|
2023
Q4 | $3.43M | Sell |
455,279
-323
| -0.1% | -$2.95K | ﹤0.01% | 3487 |
|
|
2023
Q3 | $6.83M | Sell |
455,602
-515
| -0.1% | -$9.25K | ﹤0.01% | 2720 |
|
|
2023
Q2 | $7.25M | Buy |
456,117
+351
| +0.1% | +$3.69K | ﹤0.01% | 2766 |
|
|
2023
Q1 | $3.27M | Buy |
+455,766
| New | +$3.22M | ﹤0.01% | 3446 |
|
|
2022
Q4 | – | Sell |
-12,446
| Closed | -$118K | – | 5951 |
|
|
2022
Q3 | $118K | Sell |
12,446
-8,971
| -42% | -$118K | ﹤0.01% | 5646 |
|
|
2022
Q2 | $257K | Sell |
21,417
-5,010
| -19% | -$52.5K | ﹤0.01% | 5506 |
|
|
2022
Q1 | $346K | Sell |
26,427
-22,061
| -45% | -$323K | ﹤0.01% | 5584 |
|
|
2021
Q4 | $854K | Sell |
48,488
-39,982
| -45% | -$800K | ﹤0.01% | 4984 |
|
|
2021
Q3 | $1.92M | Buy |
88,470
+6,474
| +8% | +$165K | ﹤0.01% | 4238 |
|
|
2021
Q2 | $2.87M | Sell |
81,996
-58,008
| -41% | -$3.12M | ﹤0.01% | 3867 |
|
|
2021
Q1 | $13.8M | Buy |
140,004
+1,290
| +0.9% | +$155K | ﹤0.01% | 2270 |
|
|
2020
Q4 | $15M | Buy |
138,714
+42,857
| +45% | +$5.3M | ﹤0.01% | 2098 |
|
|
2020
Q3 | $9.87M | Sell |
95,857
-18,113
| -16% | -$2.71M | ﹤0.01% | 2334 |
|
|
2020
Q2 | $23.8M | Buy |
113,970
+23,282
| +26% | +$4.12M | 0.01% | 1543 |
|
|
2020
Q1 | $8.86M | Sell |
90,688
-23,648
| -21% | -$2.76M | ﹤0.01% | 2171 |
|
|
2019
Q4 | $13.2M | Buy |
114,336
+61,036
| +115% | +$5.38M | ﹤0.01% | 2225 |
|
|
2019
Q3 | $2.9M | Buy |
53,300
+27,033
| +103% | +$3.05M | ﹤0.01% | 3270 |
|
|
2019
Q2 | $3.12M | Buy |
26,267
+14,099
| +116% | +$1.17M | ﹤0.01% | 3216 |
|
|
2019
Q1 | $638K | Buy |
12,168
+3,955
| +48% | +$160K | ﹤0.01% | 4296 |
|
|
2018
Q4 | $258K | Buy |
8,213
+6,750
| +461% | +$275K | ﹤0.01% | 4703 |
|
|
2018
Q3 | $88K | Buy |
+1,463
| New | +$82.2K | ﹤0.01% | 5175 |
|
|
2018
Q2 | – | Sell |
-63,455
| Closed | -$3.68M | – | 5622 |
|
|
2018
Q1 | $3.68M | Buy |
63,455
+53,722
| +552% | +$3.34M | ﹤0.01% | 3138 |
|
|
2017
Q4 | $341K | Buy |
+9,733
| New | +$320K | ﹤0.01% | 5099 |
|
|
2017
Q3 | – | Sell |
-16,803
| Closed | -$420K | – | 6634 |
|
|
2017
Q2 | $420K | Buy |
+16,803
| New | +$460K | ﹤0.01% | 5237 |
|
|
2017
Q1 | – | Sell |
-3,725
| Closed | -$108K | – | 6720 |
|
|
2016
Q4 | $108K | Buy |
3,725
+448
| +14% | +$14.6K | ﹤0.01% | 6099 |
|
|
2016
Q3 | $135K | Sell |
3,277
-3,485
| -52% | -$132K | ﹤0.01% | 6070 |
|
|
2016
Q2 | $214K | Sell |
6,762
-14,457
| -68% | -$653K | ﹤0.01% | 5643 |
|
|
2016
Q1 | $1.1M | Buy |
21,219
+2,735
| +15% | +$153K | ﹤0.01% | 4001 |
|
|
2015
Q4 | $1.76M | Buy |
18,484
+3,274
| +22% | +$288K | ﹤0.01% | 3751 |
|
|
2015
Q3 | $1.25M | Sell |
15,210
-6,920
| -31% | -$884K | ﹤0.01% | 4251 |
|
|
2015
Q2 | $3.59M | Buy |
+22,130
| New | +$7.47M | ﹤0.01% | 3258 |
|
|
2015
Q1 | – | Sell |
-17,586
| Closed | -$9.5M | – | 7045 |
|
|
2014
Q4 | $9.5M | Sell |
17,586
-1,942
| -10% | -$749K | ﹤0.01% | 2379 |
|
|
2014
Q3 | $6.68M | Buy |
+19,528
| New | +$5.81M | ﹤0.01% | 2738 |
|
Goldman Sachs's ADVM Position: Q4 2025 in Review
Goldman Sachs sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 402,581 shares — an estimated $1.82M sold.
Goldman Sachs first reported a position in ADVM in Q3 2014 and held it in 39 quarters. The position peaked at $23.8M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Goldman Sachs reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Goldman Sachs sold 402,581 Adverum Biotechnologies shares in Q4 2025, an estimated $1.82M.
- Goldman Sachs first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 39 quarters.
- Goldman Sachs's Adverum Biotechnologies position peaked at $23.8M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.